Year Founded
2009
Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Small molecule

Solvotrin Therapeutics General Information

Commercialized Active Iron products in 12 markets worldwide. Developing Active Iron 2.0 and anti-inflammatory compounds. Lead anti-inflammatory compound shows efficacy in CTCL cell lines without affecting non-malignant cells.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Cork,
Ireland

Drug Pipeline

Active Iron
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Solvotrin Therapeutics's pipeline data

Book a demo

Key Partnerships

Fosun Pharma, Market Performance Group, Amophar, MMDS, MGC Distributors, BioNat, Fideschem Inc, Pharmed Group, Eb Vertrieb

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Solvotrin Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Solvotrin Therapeutics's complete valuation and funding history, request access »

Solvotrin Therapeutics Investors

RAB Capital
Investor Type: Venture Capital
Holding: Minority
Elkstone Ventures
Investor Type: Venture Capital
Holding: Minority